Floatz logo

Alemtuzumab

Bone Marrow Failure Syndrome

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkinsmonoclonal_antibodyPhase 2/3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Bone Marrow Failure Syndrome cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2/3BBB
Cyclophosphamide
Memorial Sloan Kettering Cancer Center
Phase 2/3BBB
Thiotepa
Fred Hutchinson Cancer Center
Phase 2BB
Busulfanum
Memorial Sloan Kettering Cancer Center
Phase 2/3BB
Methotrexate
Fred Hutchinson Cancer Center
Phase 2BB

View all 30 →

Same molecule, other indications

Alemtuzumab is also rated in:

relapsing-remitting multiple sclerosisActive
BBB
Indicative · Phase 4
73 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative · Phase 2
71 / 100
View asset →
chronic myeloid leukemiaActive
BB
Indicative · Phase 2/3
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →